[go: up one dir, main page]

RU2006145875A - Композиция для контроля нейропатической боли - Google Patents

Композиция для контроля нейропатической боли Download PDF

Info

Publication number
RU2006145875A
RU2006145875A RU2006145875/04A RU2006145875A RU2006145875A RU 2006145875 A RU2006145875 A RU 2006145875A RU 2006145875/04 A RU2006145875/04 A RU 2006145875/04A RU 2006145875 A RU2006145875 A RU 2006145875A RU 2006145875 A RU2006145875 A RU 2006145875A
Authority
RU
Russia
Prior art keywords
use according
och
group
compound
linear
Prior art date
Application number
RU2006145875/04A
Other languages
English (en)
Inventor
Масаказу ЕСИМУРА (JP)
Масаказу ЕСИМУРА
Норимаса КАНАМИТСУ (JP)
Норимаса КАНАМИТСУ
Йутака ИТСУДЗИ (JP)
Йутака ИТСУДЗИ
Такаси ОСАКА (JP)
Такаси ОСАКА
Мотоко КАВАСИМА (JP)
Мотоко КАВАСИМА
Original Assignee
Маруиси Фармасьютикал Ко., Лтд. (Jp)
Маруиси Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Маруиси Фармасьютикал Ко., Лтд. (Jp), Маруиси Фармасьютикал Ко., Лтд. filed Critical Маруиси Фармасьютикал Ко., Лтд. (Jp)
Publication of RU2006145875A publication Critical patent/RU2006145875A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C07D209/64—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (14)

1. Применение соединения, представленное формулой (I)
Figure 00000001
где R1 и R2 могут быть одинаковыми или разными и представляют С1-6алкильные группы, или R1 и R2 вместе формируют 6-членный конденсированный цикл с конъюгированными двойными связями или они вместе формируют звено -O-СН2-O-, -СН2-СН2-СН2- или СН2-O-СН2-;
Х является галогеном или С1-6алкокси или вместе с фенильным звеном, к которому Х присоединен, формирует группу (2)
Figure 00000002
;
m является целым числом от 0 до 2, причем, когда Х является С1-6алкокси-группой, m равно 0 или 1;
Y является
Figure 00000003
,
где R3 является линейным или разветвленным С1-6алкилом, линейным или разветвленным С3-6алкенилом, линейным или разветвленным С3-6алкинилом, С5-6циклоалкилом,
Figure 00000004
,
где R4 является С1-4 алкилом или
Figure 00000005
, или
и
Figure 00000006
Z является кислородом или серой, или его соль для производства фармацевтической композиции для контроля над нейропатической болью.
2. Применение по п.1, где R1 и R2 оба являются метилом.
3. Применение по п.1, где R1 и R2 взятые вместе формируют звено -O-СН2-O-, -СН2-СН2-СН2- или -СН2-O-СН2-.
4. Применение по п.1, где Х является галогеном в пара- и/или метаположении фенильного звена.
5. Применение по п.1, где Х является алкокси- в параположении фенильного звена.
6. Применение по п.1, где Х является водородом или формирует вместе с фенильным звеном, к которому Х присоединен, группу
Figure 00000007
7. Применение по любому из пп.1-6, где Y является
Figure 00000008
и R3 выбирают из группы, состоящей из линейного С1-6алкила, -СН(СН3)2, -СН2СН=СН2, -СН2-С≡CH, С(=O)СН3 и групп
Figure 00000009
,
циклопентила или циклогексила.
8. Применение по любому из пп.1-6, где Y является
Figure 00000010
9. Применение по любому из пп.1-6, где Z является кислородом.
10. Применение по п.1, где соединение формулы (I) выбирают из приведенных ниже
Figure 00000011
, где
R5 L
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000013
Figure 00000015
Figure 00000013
Figure 00000016
Figure 00000013
Figure 00000017
Figure 00000013
Figure 00000018
Figure 00000013
Figure 00000012
Figure 00000019
Figure 00000020
Figure 00000013
Figure 00000021
Figure 00000022
Figure 00000021
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000021
Figure 00000025
Figure 00000021
Figure 00000026
Figure 00000021
Figure 00000027
Figure 00000021
Figure 00000028
Figure 00000024
Figure 00000029
11. Применение по п.1, где соединение формулы (I) выбирают из приведенных ниже
Figure 00000030
, где
М R5 L CH2CH2CH2
Figure 00000024
Figure 00000031
 CH2CH2CH2
Figure 00000015
Figure 00000032
 CH2CH2CH2
Figure 00000015
Figure 00000033
 CH2CH2CH2
Figure 00000015
Figure 00000034
 OCH2O
Figure 00000024
Figure 00000035
 OCH2O
Figure 00000015
Figure 00000036
 CH2OCH2
Figure 00000015
Figure 00000037
 CH2OCH2
Figure 00000015
Figure 00000038
 CH=CH-CH=CH
Figure 00000039
Figure 00000040
12. Способ контроля над нейропатической болью, который включает назначение эффективного количества соединения, определенного в п.1, субъекту, нуждающемуся в контроле над болью.
13. Соединение, выбранное из группы, состоящей из
Figure 00000041
, где
R5 L
Figure 00000042
Figure 00000040
Figure 00000024
Figure 00000038
Figure 00000015
Figure 00000038
Figure 00000015
Figure 00000043
Figure 00000024
Figure 00000029
Figure 00000044
, где
М R5 L CH2CH2CH2
Figure 00000015
Figure 00000038
 CH2CH2CH2
Figure 00000015
Figure 00000033
 CH2CH2CH2
Figure 00000015
Figure 00000034
 OCH2O
Figure 00000015
Figure 00000038
 CH2OCH2
Figure 00000015
Figure 00000045
 CH2OCH2
Figure 00000015
Figure 00000038
 CH=CH-CH=CH
Figure 00000046
Figure 00000045
14. Соединение по п.13, которое выбирают из группы, состоящей из
Figure 00000041
, где
R5 L
Figure 00000024
Figure 00000038
Figure 00000015
Figure 00000038
Figure 00000024
Figure 00000029
Figure 00000047
, где
М R5 L CH2CH2CH2
Figure 00000015
Figure 00000038
 CH2CH2CH2
Figure 00000015
Figure 00000033
 CH2CH2CH2
Figure 00000015
Figure 00000034
 OCH2O
Figure 00000015
Figure 00000038
 CH2OCH2
Figure 00000015
Figure 00000038
RU2006145875/04A 2004-05-24 2005-05-23 Композиция для контроля нейропатической боли RU2006145875A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-153206 2004-05-24
JP2004153206 2004-05-24

Publications (1)

Publication Number Publication Date
RU2006145875A true RU2006145875A (ru) 2008-06-27

Family

ID=35428364

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006145875/04A RU2006145875A (ru) 2004-05-24 2005-05-23 Композиция для контроля нейропатической боли

Country Status (14)

Country Link
US (1) US20080021042A1 (ru)
EP (1) EP1749817A4 (ru)
JP (1) JPWO2005113501A1 (ru)
CN (1) CN1956955A (ru)
AU (1) AU2005245292A1 (ru)
BR (1) BRPI0511546A (ru)
CA (1) CA2563968A1 (ru)
EC (1) ECSP067107A (ru)
IL (1) IL178814A0 (ru)
MX (1) MXPA06013766A (ru)
NO (1) NO20064868L (ru)
RU (1) RU2006145875A (ru)
TW (1) TW200602318A (ru)
WO (1) WO2005113501A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2343145C2 (ru) * 2002-11-26 2009-01-10 Маруиси Фармасьютикал Ко., Лтд. Производные изоиндолина
EP2044019A1 (en) * 2006-07-12 2009-04-08 Astra Zeneca AB 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents
CN104803905B (zh) * 2015-04-17 2017-10-10 复旦大学 一种合成异吲哚啉‑1‑酮衍生物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2117740B1 (ru) * 1970-12-14 1974-04-12 Rhone Poulenc Sa
DE3378763D1 (en) * 1982-04-02 1989-02-02 Takeda Chemical Industries Ltd Condensed pyrrolinone derivatives, and their production
WO1984003089A1 (fr) * 1983-02-05 1984-08-16 Takeda Chemical Industries Ltd Derives condenses de pyrrolinone
IL133621A0 (en) * 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
RU2343145C2 (ru) * 2002-11-26 2009-01-10 Маруиси Фармасьютикал Ко., Лтд. Производные изоиндолина

Also Published As

Publication number Publication date
ECSP067107A (es) 2007-02-28
IL178814A0 (en) 2007-03-08
NO20064868L (no) 2007-02-26
JPWO2005113501A1 (ja) 2008-03-27
TW200602318A (en) 2006-01-16
MXPA06013766A (es) 2007-02-08
EP1749817A4 (en) 2007-12-26
AU2005245292A1 (en) 2005-12-01
BRPI0511546A (pt) 2008-01-02
CA2563968A1 (en) 2005-12-01
WO2005113501A1 (ja) 2005-12-01
US20080021042A1 (en) 2008-01-24
EP1749817A1 (en) 2007-02-07
CN1956955A (zh) 2007-05-02

Similar Documents

Publication Publication Date Title
EA200970609A1 (ru) Инсектицидные соединения
EA200601620A1 (ru) 5,6-диалкил-7-аминотриазолопиримидины, способ их получения и их применение для борьбы с патогенными растениями, а также содержащие их средства
EA201200826A1 (ru) Инсектицидные соединения, основанные на производных изоксазолина
RU2009109160A (ru) Инсектицидные изоксазолины
RU2343151C3 (ru) Цианоантраниламидные инсектициды
EP2361503A3 (en) N-2-(hetero)arylethylcarboxamide derivative, and pest-controlling agent comprising the same
RU2013114351A (ru) Пестицидные композиции
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
JO2935B1 (en) 6- Tertiary azulo pyridazine sulfanil benzothiazole and benzimidazole derivatives, method of preparation, use as pharmaceutical products, pharmaceutical compositions and new use in particular as met inhibitors (methionine)
AR077143A1 (es) Compuestos insecticidas
PL1717237T3 (pl) Antraniloamidy, sposób ich wytwarzania oraz pestycydy je zawierające
BRPI0507914A8 (pt) Moduladores
RU2004130840A (ru) Бензамиды и композиции на их основе для использования в качестве фунгицидов
RU2005108046A (ru) 1, 2, 3-триазольные производные, обладающие бактерицидной (например, фунгицидной)активностью
RU2013138372A (ru) Производные азетидина, применяемые для лечения метаболических и воспалительных заболеваний
RU2009110997A (ru) Инсектицидные бензамидины
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
EA200800813A1 (ru) Фунгицидные пиридинилоксизамещённые производные фениламидина
AR053380A1 (es) Pesticidas en fenileteres sustituidos
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
HU0201357D0 (ru)
ATE276243T1 (de) Mikrobiozide n-phenyl-n-(4-(4-pyridyl)-2- pyrimidin-2-yl)-amin-derivate
RU2006145875A (ru) Композиция для контроля нейропатической боли
EA201100227A1 (ru) Инсектицидные фенил- или пиридилпиперидины
EP2269694A3 (en) Antituberculous composition comprising oxazole compounds

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090903